MA52761A - Schéma posologique destiné au traitement de troubles liés à la pi3k - Google Patents
Schéma posologique destiné au traitement de troubles liés à la pi3kInfo
- Publication number
- MA52761A MA52761A MA052761A MA52761A MA52761A MA 52761 A MA52761 A MA 52761A MA 052761 A MA052761 A MA 052761A MA 52761 A MA52761 A MA 52761A MA 52761 A MA52761 A MA 52761A
- Authority
- MA
- Morocco
- Prior art keywords
- pi3k
- treatment
- related disorders
- dosage regimen
- regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679556P | 2018-06-01 | 2018-06-01 | |
| US201862714448P | 2018-08-03 | 2018-08-03 | |
| US201862773612P | 2018-11-30 | 2018-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52761A true MA52761A (fr) | 2021-04-14 |
Family
ID=67003653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052761A MA52761A (fr) | 2018-06-01 | 2019-05-30 | Schéma posologique destiné au traitement de troubles liés à la pi3k |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190365764A1 (fr) |
| EP (1) | EP3801533A1 (fr) |
| JP (1) | JP7455763B2 (fr) |
| KR (1) | KR20210018328A (fr) |
| CN (1) | CN112469418A (fr) |
| AU (1) | AU2019277560A1 (fr) |
| BR (1) | BR112020024427A2 (fr) |
| CA (1) | CA3101323A1 (fr) |
| CL (1) | CL2020003118A1 (fr) |
| EC (1) | ECSP20077106A (fr) |
| IL (1) | IL278889A (fr) |
| MA (1) | MA52761A (fr) |
| MX (1) | MX2020012826A (fr) |
| PE (1) | PE20211208A1 (fr) |
| PH (1) | PH12020552059A1 (fr) |
| SG (1) | SG11202011680YA (fr) |
| TW (1) | TW202015693A (fr) |
| WO (1) | WO2019232188A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087760A1 (es) | 2011-09-02 | 2014-04-16 | Incyte Corp | Heterociclilaminas como inhibidores de pi3k |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| US20210253582A1 (en) * | 2020-02-06 | 2021-08-19 | Incyte Corporation | Salts and solid forms and processes of preparing a pi3k inhibitor |
| AR127966A1 (es) | 2021-12-16 | 2024-03-13 | Incyte Corp | Formulaciones tópicas de inhibidores de pi3k-delta |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
| US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AU2010273816B2 (en) | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
| US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011075630A1 (fr) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Dérivés substitués d'aryles et d'hétéroaryles fusionnés au titre d'inhibiteurs de pi3k |
| KR102354472B1 (ko) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체 |
| WO2012068450A1 (fr) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Dérivés pyrrolopyridine et pyrrolopyrimidine à substitution cyclobutyle utilisés comme inhibiteurs des jak |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| EP2655374B1 (fr) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k |
| JP5876146B2 (ja) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| AR087760A1 (es) | 2011-09-02 | 2014-04-16 | Incyte Corp | Heterociclilaminas como inhibidores de pi3k |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| PT3262046T (pt) * | 2015-02-27 | 2020-12-24 | Incyte Corp | Sais de inibidor de pi3k e processos para a sua preparação |
-
2019
- 2019-05-30 MA MA052761A patent/MA52761A/fr unknown
- 2019-05-30 JP JP2020566893A patent/JP7455763B2/ja active Active
- 2019-05-30 WO PCT/US2019/034613 patent/WO2019232188A1/fr unknown
- 2019-05-30 PE PE2020001922A patent/PE20211208A1/es unknown
- 2019-05-30 EP EP19733240.6A patent/EP3801533A1/fr active Pending
- 2019-05-30 CA CA3101323A patent/CA3101323A1/fr active Pending
- 2019-05-30 KR KR1020207037699A patent/KR20210018328A/ko unknown
- 2019-05-30 AU AU2019277560A patent/AU2019277560A1/en active Pending
- 2019-05-30 SG SG11202011680YA patent/SG11202011680YA/en unknown
- 2019-05-30 MX MX2020012826A patent/MX2020012826A/es unknown
- 2019-05-30 BR BR112020024427-9A patent/BR112020024427A2/pt unknown
- 2019-05-30 CN CN201980048918.4A patent/CN112469418A/zh active Pending
- 2019-05-31 TW TW108118995A patent/TW202015693A/zh unknown
- 2019-05-31 US US16/428,056 patent/US20190365764A1/en active Pending
-
2020
- 2020-11-22 IL IL278889A patent/IL278889A/en unknown
- 2020-11-30 CL CL2020003118A patent/CL2020003118A1/es unknown
- 2020-11-30 EC ECSENADI202077106A patent/ECSP20077106A/es unknown
- 2020-12-01 PH PH12020552059A patent/PH12020552059A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020003118A1 (es) | 2021-04-30 |
| US20190365764A1 (en) | 2019-12-05 |
| BR112020024427A2 (pt) | 2021-03-23 |
| AU2019277560A1 (en) | 2020-12-10 |
| JP2021525757A (ja) | 2021-09-27 |
| SG11202011680YA (en) | 2020-12-30 |
| JP7455763B2 (ja) | 2024-03-26 |
| KR20210018328A (ko) | 2021-02-17 |
| PH12020552059A1 (en) | 2021-07-05 |
| EP3801533A1 (fr) | 2021-04-14 |
| PE20211208A1 (es) | 2021-07-05 |
| TW202015693A (zh) | 2020-05-01 |
| MX2020012826A (es) | 2021-03-09 |
| CN112469418A (zh) | 2021-03-09 |
| IL278889A (en) | 2021-01-31 |
| ECSP20077106A (es) | 2021-01-29 |
| CA3101323A1 (fr) | 2019-12-05 |
| WO2019232188A1 (fr) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA45192A (fr) | Traitement d'association | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA53127A (fr) | Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales | |
| IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA51613A (fr) | Polythérapie pour le traitement ou la prévention du cancer | |
| MA54559A (fr) | Polythérapie pour le traitement du cancer | |
| MA53236A (fr) | Traitement des malignités des lymphocytes b | |
| JP1671730S (ja) | 医療用加湿器用タブ用部品 | |
| MA42985A (fr) | Traitement de troubles liés à l'acide biliaire | |
| MA50495A (fr) | Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |